Showing 1 - 3 results of 3 for search 'K. Pavenski', query time: 0.02s Refine Results
  1. 1
    OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL

    OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL by M. Scully, J.L. Rubia, F. Peyvandi, S. Cataland, P. Coppo, J.A.K. Hovinga, P. Knoebl, K. Pavenski, F. Callewaert, J.M.M. Edou, R.P. Sousa

    Published 2020-11-01
    Get full text
    Article
  2. 2
    S294: LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST-HERCULES STUDY

    S294: LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST-HERCULES STUDY by M. Scully, J. de la Rubia, K. Pavenski, A. Metjian, P. Knöbl, F. Peyvandi, S. Cataland, P. Coppo, J. A. Kremer Hovinga, R. De Passos Sousa, F. Callewaert, S. Gunawardena, J. Lin

    Published 2022-06-01
    Get full text
    Article
  3. 3
    Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura

    Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocyt... by L. Kaynar, P. Coppo, M. Scully, J. De La Rubia, F. Peyvandi, S. Cataland, J. A. Kremer Hovinga, P. Knoebl, K. Pavenski, J. Minkue Mi Edou, F. Callewaert, R. De Passos Sousa

    Published 2020-10-01
    Get full text
    Article

Search Tools: